Pen Needles Market (2026 - 2033)

Pen Needles Market Summary

The global pen needles market size was valued at USD 4.8 billion in 2025 and is projected to grow from USD 5.3 billion in 2026 to USD 9.9 billion by 2033, at a CAGR of 9.4% from 2026 to 2033. Europe pen needles market held the largest share of 36.4% of the global pen needles market in 2025. The increasing prevalence of diabetes is driving the demand for pen needles.

According to the International Diabetes Federation (IDF), the number of people living with diabetes worldwide is projected to reach approximately 642 million by 2040, positioning the pen needles market for significant growth. As diabetes rates rise globally, the demand for efficient insulin delivery solutions is expected to fuel the market expansion at a strong rate over the forecast period. Pen injectors are widely used by diabetic individuals to deliver insulin or other medications, making them a preferred choice for diabetes management. The global surge in diabetes cases, particularly linked to the growing obesity epidemic, has greatly influenced the demand for insulin pens and, by extension, pen needles. Obesity is considered a major risk factor for diabetes. According to Diabetes.co.uk, it accounts for 80-85% of the risk of developing Type 2 diabetes. As the global population becomes increasingly obese, the incidence of diabetes has been rising, creating a large demand for insulin delivery devices such as pen needles.

Technological advancements and continuous innovation in pen needles are further driving market growth, as manufacturers focus on improving patient comfort, safety, and ease of use. Key developments include ultra-fine needles, shorter needle lengths to minimize pain, and advanced designs that reduce the risk of intramuscular injections. Companies are also introducing features such as smoother and flatter needle bases for improved skin contact, along with safety mechanisms that prevent accidental needlestick injuries. For instance, in November 2024, evercare pen needles were introduced as an advanced solution for type I diabetes patients. These pen needles are designed to enhance patient comfort, lower the risk of intramuscular injections, and reduce accidental needlestick injuries. In addition, the product features a wider grip design, making it especially convenient and user-friendly for elderly patients and individuals with limited dexterity.

The market is expected to continue expanding, driven by the increasing global prevalence of diabetes, the growing obesity epidemic, and continuous innovations in needle technology. As more patients switch from syringes to pen needles for insulin delivery, the demand for these devices likely to remain high. The industry is expected to see further advancements that improve patient comfort, safety, and the overall effectiveness of diabetes management. Companies in the pen needles market must continue to focus on product innovation and ensuring a steady supply to meet the needs of a growing diabetic population worldwide.

Regulatory frameworks and product approval processes play a crucial role in shaping product development, market entry strategies, and patient safety standards within the pen needles market. Regulatory approvals, particularly FDA clearances, are essential for ensuring the safety, quality, and effectiveness of medical devices before commercialization. For instance, in January 2024, KB received FDA 510(k) clearance for its Safety Insulin Pen Needle, highlighting the growing emphasis on regulatory compliance across the industry. Such approvals assist companies strengthen their product portfolios while enhancing confidence among healthcare providers and patients. In addition, stringent regulatory standards encourage manufacturers to develop safer, more reliable, and technologically advanced pen needle solutions, thereby supporting overall market growth.

Strategic mergers, acquisitions, and business expansion activities are increasingly influencing the competitive landscape of the pen needles market as companies aim to strengthen their technological expertise, broaden product offerings, and expand their global footprint. For instance, in August 2024, MTD Group acquired Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems businesses. Through this acquisition, MTD increased its production capacity to more than 2.5 billion units and further strengthened its diabetes and obesity care portfolio by integrating Ypsomed’s operations into its European network. Such strategic initiatives help companies improve operational capabilities, enhance manufacturing efficiency, and accelerate product innovation, thereby intensifying market competition and supporting long-term industry growth.

Market Dynamics

Pen needles are gaining significant traction as they enable patients with diabetes and other chronic conditions requiring injectable therapies to administer medications safely, accurately, and conveniently. These devices incorporate advanced features such as ultra-thin needle designs, shorter needle lengths, silicone-coated surfaces, safety-engineered mechanisms, and universal compatibility with insulin and GLP-1 injection pens to enhance patient comfort and improve treatment adherence. Pen needles help healthcare providers and patients address the growing global burden of diabetes by supporting precise drug delivery, minimizing injection-related pain, reducing the risk of needlestick injuries, and facilitating self-administration in homecare settings. Their ease of use, improved safety profile, and ability to support long-term disease management continue to drive adoption across hospitals, clinics, and home healthcare environments

Market Concentration & Characteristics

The pen needles market is moderately consolidated, with major companies such as Becton, Dickinson and Company, Novo Nordisk, Ypsomed, and Owen Mumford holding significant market shares. These companies offer a wide range of standard and safety pen needles designed for insulin delivery and other injectable therapies used in diabetes management, obesity treatment, fertility care, and chronic disease management. Their product portfolios include ultra-thin, short-length, and dual-protection safety pen needles developed to improve injection comfort, dosing accuracy, patient safety, and treatment adherence.

The pen needles market is witnessing a high degree of innovation driven by the growing demand for safer, more comfortable, and patient-friendly insulin delivery solutions for diabetes and obesity management. Manufacturers are increasingly focusing on developing ultra-thin, shorter-length, and dual-protection safety pen needles designed to minimize injection pain, improve dose accuracy, reduce needle-stick injuries, and enhance patient adherence to long-term injectable therapies. For instance, Terumo Corporation launched FineGlide sterile pen needles in India for patients requiring insulin injections and self-medication therapies. The product was developed with Thin Wall Technology, high-grade silicone coating, and multi-size compatibility to improve injection comfort, enhance drug compliance, and support growing demand for patient-friendly diabetes management solutions.

The market is witnessing a significant rise in partnerships and collaborations as medical device manufacturers, pharmaceutical companies, diabetes care organizations, and healthcare providers work together to improve insulin delivery solutions and enhance diabetes management outcomes. Strategic collaborations are increasingly focused on developing advanced injection technologies, improving compatibility between insulin pens and pen needles, expanding patient access to self-administration devices, and strengthening diabetes care education programs across emerging and developed healthcare markets. For instance, embecta announced a major partnership expansion with Direct Relief to improve global access to diabetes care and insulin delivery support for underserved communities. The collaboration focuses on strengthening diabetes management programs and expanding access to essential injection devices, including pen needles, across vulnerable patient populations worldwide.

The market operates within a highly regulated framework governed by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and other international healthcare regulatory authorities that focus on product safety, sterility, biocompatibility, needle quality, patient safety, and infection control standards. Regulatory oversight has increased significantly due to the growing use of pen needles for insulin delivery, GLP-1 therapies, and self-administration treatments in diabetes and obesity management. Regulatory agencies are placing stronger emphasis on needle-stick injury prevention, single-use safety standards, manufacturing quality compliance, labeling requirements, and compatibility validation with insulin pen devices to ensure safe and effective drug delivery across healthcare and homecare settings.

The industry faces growing competition from alternative drug delivery approaches such as traditional insulin syringes, insulin pumps, patch pumps, needle-free injectors, wearable drug delivery devices, and emerging oral diabetes therapies, which are increasingly being adopted to improve patient convenience and reduce dependency on conventional pen needle-based injections. Traditional insulin syringes continue to remain widely used in cost-sensitive and developing healthcare markets due to their lower pricing and broad availability. In addition, the increasing adoption of continuous subcutaneous insulin infusion systems and smart insulin pumps is gradually reducing reliance on disposable pen needles among certain diabetic patient populations seeking automated glucose management and reduced injection frequency.

The pen needles market is witnessing significant regional expansion as medical device manufacturers and diabetes care companies strengthen their presence across emerging healthcare markets in Asia-Pacific, Latin America, the Middle East, and Eastern Europe to meet the growing demand for insulin delivery and self-injection therapies. Rising prevalence of diabetes and obesity, improving healthcare infrastructure, increasing healthcare expenditure, and growing awareness regarding self-administration treatments are encouraging companies to establish strategic partnerships, local distribution networks, and manufacturing facilities in high-growth regions. In addition, expanding access to diabetes diagnosis and treatment programs across developing countries is supporting the adoption of insulin pens and compatible pen needle products in both hospital and homecare settings.

Analyst Perspective

The pen needles market is positioned at the intersection of several long-term healthcare trends, including the rising global prevalence of diabetes, increasing adoption of injectable therapies, and growing emphasis on patient-centric disease management. The expanding population of individuals requiring insulin, GLP-1 receptor agonists, and other injectable medications is creating significant opportunities for pen needle manufacturers as healthcare systems focus on improving treatment adherence and self-care practices. In addition, the growing shift toward home-based healthcare, coupled with increasing awareness of proper injection techniques, is driving demand for user-friendly and comfortable drug delivery solutions. Continuous product innovations such as ultra-thin needles, shorter needle lengths, enhanced lubrication technologies, and safety-engineered pen needles are improving patient comfort, reducing injection-related anxiety, and minimizing the risk of needlestick injuries.

Product Insights

Based on product, the standard pen needles segment led the market with the largest revenue share of 87.0% in 2025. The growth is owing to its extensive usage among insulin-dependent diabetic patients and the strong preference for affordable, convenient, and easy-to-use injection devices. Standard pen needles are gaining significant traction in the market due to their broad compatibility with leading insulin pens, widespread availability across hospitals, retail pharmacies, and online channels, and their lower cost compared to safety pen needles. Healthcare providers and patients continue to prefer standard pen needles for routine insulin administration because they offer simple handling, reliable drug delivery, and minimal training requirements, making them highly suitable for homecare settings and long-term diabetes management. The segment is also benefiting from increasing adoption of shorter and thinner needle variants designed to reduce injection pain, improve patient comfort, and enhance treatment adherence. Manufacturers are continuously introducing advanced standard pen needles with ultra-thin wall technology and improved flow mechanisms to strengthen product demand.

The safety pen needles segment is expected to witness the fastest CAGR of 11.1% over the forecast period. The growth is attributed to the increasing focus on needlestick injury prevention, rising awareness regarding injection safety, and growing regulatory emphasis on protecting healthcare workers and patients from accidental needle exposure. Safety pen needles are gaining strong traction in the market because they are equipped with automatic shielding or protective locking mechanisms that minimize the risk of contamination, infection transmission, and accidental injuries during and after insulin administration. Hospitals, clinics, and home healthcare providers are increasingly adopting these devices to improve patient safety and comply with stringent healthcare safety regulations. As healthcare systems continue to prioritize safe drug delivery practices, the demand for advanced safety-engineered injection devices is increasing rapidly. In addition, the expanding geriatric population and growing preference for home-based diabetes management are encouraging the adoption of easy-to-use and safer pen needle solutions.

Needle Length Insights

Based on needle length, the 5mm segment led the market with the largest revenue share of 20.7% in 2025, due to the increasing preference for shorter needle lengths that improve patient comfort, reduce injection pain, and support effective insulin delivery across a broad patient population. The growing adoption of 5mm pen needles is strongly driven by rising diabetes prevalence, increasing demand for self-injection therapies, and the shift toward patient-friendly insulin administration devices. Compared to other needles, 5mm pen needles are widely preferred because they minimize needle anxiety, reduce the risk of intramuscular injections, and enhance convenience for both adult and pediatric diabetic patients. Furthermore, it offers an optimal balance between injection comfort, safety, and effective insulin absorption. These needles are suitable for patients with different body types and are increasingly recommended by healthcare professionals to reduce injection-related complications such as bruising and tissue damage.

The 4mm segment is expected to witness the fastest CAGR over the forecast period, owing to the increasing preference for ultra-short needle lengths that enhance patient comfort, reduce injection pain, and improve adherence to insulin therapy. The growing adoption of 4mm pen needles is primarily driven by rising diabetes prevalence, increasing demand for self-administration of insulin, and growing awareness among healthcare professionals regarding the clinical benefits of shorter needles. Compared to longer needle variants, 4mm pen needles reduce the risk of intramuscular injections, minimize skin trauma, and support safer and more consistent subcutaneous insulin delivery across patients with different body types, including pediatric and elderly populations. Their ability to provide effective insulin absorption with less discomfort is significantly contributing to segment growth.

Therapy Insights

Based on therapy, the insulin segment led the market with the largest revenue share of 85.6% in 2025 and expected to witness fastest CAGR over the forecast period, driven by the rising global prevalence of diabetes and the growing dependence on insulin therapy for effective blood glucose management. The increasing number of patients diagnosed with Type 1 and Type 2 diabetes, along with the expanding geriatric population and rising obesity rates, has significantly accelerated the demand for insulin delivery devices such as pen needles. Insulin therapies require frequent and long-term administration, making pen needles an essential component in diabetes care. The growing preference for insulin pens over conventional vial-and-syringe methods due to better convenience, portability, dosing accuracy, and ease of self-administration is further supporting segment growth.

The glucagon-like-peptide-1 (GLP-1) segmentis anticipated to grow at significant rate over the forecast period. Increasing adoption of GLP-1 receptor agonist therapies for the treatment of Type 2 diabetes and obesity drives the growth of market. The growing prevalence of obesity, rising diabetic population, and increasing awareness regarding weight management therapies are significantly contributing to segment growth. GLP-1 therapies have gained substantial attention due to their effectiveness in improving blood glucose control, supporting weight loss, and reducing cardiovascular risks, leading to higher prescription rates globally. As most GLP-1 drugs are administered through injectable pens, the demand for compatible pen needles is increasing significantly alongside the expansion of this therapy segment.

Regional Insights

The European pen needles market accounted for the largest share of 36.4% in 2025. The growth is being reshaped by high prevalence of diabetes, increasing adoption of self-injection devices, and strong healthcare infrastructure. The demand for user-friendly and safety-focused products, such as safety pen needles and shorter needle lengths, further drove market growth, alongside regulatory support for innovation.

The UK pen needles marketis steadily growing, supported by government initiatives focused on investing in diabetes care and research to enhance treatment options for diabetic patients. The rising number of diabetes cases in the region is a key driver of market expansion. According to Diabetes UK, over 4.3 million people in the UK are affected by diabetes, with an additional 850,000 individuals potentially living undiagnosed. This rising patient population contributes to the rising consumption of pen needles further fuels the market growth.

The pen needles market in Germany is expected to grow in the forecast period. The growth is mainly attributed to the rising prevalence of diabetes, increasing adoption of self-injection devices, and growing awareness about the benefits of pen needles for managing chronic conditions. Additionally, the demand for safer and more comfortable injection options further fuels market growth. According to the International Diabetes Federation, Germany has approximately 7.5 million people living with diabetes, contributing to the expanding market for pen needles.

North America Pen Needles Market Trends

Pen needles market in North America accounted for the significamt revenue share of in 2025. This growth was fueled by the demand for pen needles, insulin syringes, and safety solutions such as safety lancets, pen needles, and immunization products, all distributed under the Droplet and DropSafe brands. Known for their patented solutions, these brands prioritize comfort and ease of use for both patients and healthcare professionals. Droplet, the fastest-growing pen needle brand in North America, is the second-largest supplier in the US. Additionally, MTD has secured a 50% market share in safety lancets globally and 15% in personal lancets.

U.S. Pen Needles Market Trends

The pen needles market in U.S. is experiencing steady growth, driven by the increasing prevalence of chronic conditions such as diabetes. In 2024, the market is expected to expand as more patients adopt insulin pens for self-injection due to their convenience and ease of use. The availability of various needle lengths, including shorter, more comfortable options like 5mm, has further fueled growth. Additionally, the demand for safety features, such as safety pen needles, is rising among healthcare providers to reduce needle-stick injuries. Major brands such as Droplet and innovations in product design continue to shape the market.

Asia Pacific Pen Needles Market Trends

The pen needles market in Asia Pacificis anticipated to see strong growth during the forecast period. The increasing preference for pen needles over traditional syringes and vials is a key factor fueling this growth. Additionally, the rising elderly population in the region contributes significantly to the demand for pen needles, as older individuals often require more convenient and user-friendly injection options. The growing awareness of diabetes management and self-injection devices further supports the expansion of the market. As healthcare infrastructure improves, the adoption of pen needles is expected to continue to rise across the region.

Japan pen needles market is experiencing growth due to ongoing technological advancements in medical devices. Innovations in needle design, such as shorter, finer needles to reduce pain and improved ease of use, are contributing to higher adoption rates. Additionally, the integration of smart technology into pen needles to improve dose accuracy and patient compliance is further driving market expansion. Japan’s large diabetic population, estimated at over 7 million people, is also a significant factor.

The pen needles market in India is expected to register the fastest growth in the Asia Pacific market over the forecast period. The growth is driven by the rising prevalence of diabetes and increasing adoption of self-injection devices. India has over 77 million people living with diabetes, making it one of the countries with the highest number of diabetic patients globally. According to the International Diabetes Federation, this number is expected to rise significantly in the coming years. As the demand for convenient, painless, and user-friendly insulin delivery options grows, pen needles are becoming increasingly popular. Additionally, government initiatives and improved healthcare infrastructure are contributing to the market’s expansion in the country.

Latin America Pen Needles Market Trends

The region is an emerging market for pen needlesand is expected to grow at the significant rate due to the rising prevalence of diabetes and other chronic conditions requiring injectable therapies. Increasing awareness regarding self-administration of insulin, growing adoption of injectable drug delivery devices, and improving access to healthcare services are supporting market expansion across both urban and rural populations. In addition, the growing elderly population, which is more susceptible to diabetes and related disorders, is contributing to the increased demand for pen needles in clinical as well as homecare settings.

Brazil pen needles market is growing steadily. Growing awareness regarding diabetes management, expanding access to insulin therapies, and the increasing adoption of injection pens are contributing significantly to market growth. In addition, the country’s large aging population, rising obesity rates, and increasing burden of chronic diseases are driving the demand for pen needles in both healthcare facilities and homecare settings. Government healthcare programs aimed at improving access to diabetes treatment and expanding public healthcare services are further supporting market expansion. Furthermore, rising investments by international and domestic medical device companies, along with growing awareness regarding safe and convenient injection practices, are expected to create favorable growth opportunities for the pen needles market in Brazil during the forecast period.

Middle East & Africa Pen Needles Market Trends

The pen needles market in Middle East and Africa (MEA) is growing steadily. Increasing awareness of diabetes management, improving access to healthcare services, and the growing adoption of self-injection devices are supporting the demand for pen needles in both hospital and homecare settings. In addition, the expanding geriatric population and rising incidence of obesity are contributing to the increasing use of insulin and other injectable medications, thereby driving market growth. Government initiatives focused on strengthening healthcare infrastructure, improving chronic disease management programs, and expanding healthcare coverage are further supporting the adoption of advanced drug delivery solutions across the region.

The pen needles market in Saudi Arabia is experiencing notable growth, supported by the rising prevalence of obesity and other chronic conditions across the country. Increasing demand for insulin therapy, growing awareness regarding self-administration of injectable drugs, and the expanding adoption of advanced drug delivery devices are contributing significantly to market expansion. In addition, the country’s growing elderly population and increasing incidence of chronic diseases are driving the demand for pen needles in hospitals, clinics, and homecare settings.

Key Pen Needles Company Insight

The pen needles market is highly competitive, with key players focusing on strengthening their market position through technological advancements, strategic collaborations, and global expansion initiatives. Companies are increasingly investing in advanced pen needle technologies such as ultra-thin and short-length needles, safety pen needles, dual-ended needle designs, and enhanced comfort-focused delivery systems to improve patient convenience, reduce injection pain, minimize needlestick injuries, and support better treatment adherence among patients requiring regular injectable therapies such as diabetes, obesity, fertility, and hormone treatments.

Key Pen Needles Companies

The following key companies have been profiled for this study on the pen needles market.

• Novo Nordisk A/S

• Becton Dickinson and Company

• Terumo Corp.

• Owen Mumford Ltd.

• Ypsomed

• B. Braun Melsungen AG

• HTL-STREFA

• UltiMed, Inc.

• Allison Medical, Inc.

• Artsana S.p.A.

Competitive Benchmarking

Recent Development

• In September 2025, Sandstone Diagnostics announced the debut of its EasyDrip Plus Pen Needles in Uzbekistan to strengthen access to advanced diabetes injection solutions in the region. The pen needles are designed with enhanced thin-wall and multi-bevel technology to improve injection comfort, reduce pain, and support better insulin delivery efficiency for diabetes patients.

• In August 2025, Trividia Health UK announced the launch of its TRUEplus 5-Bevel Pen Needles in the UK, marking the product’s first availability outside the U.S. The new pen needle range is designed to improve injection comfort through advanced 5-bevel needle technology and offers multiple gauge and size options at a lower cost for diabetes patients.

• In October 2024, Apollo Medical Technologies announced the launch of its new Pro-Shield Duo Safety Pen Needle, scheduled for early 2025. The product features an advanced dual-end shielding mechanism designed to reduce accidental needle-stick injuries and improve safety for both healthcare professionals and patients.

Pen Needles Market Report Scope

Global Pen Needles Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the global pen needles market report based on product, needle length, therapy, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Standard Pen Needles

  • Safety Pen Needles

• Needle Length Outlook (Revenue, USD Billion, 2021 - 2033)

  • 4mm

  • 5mm

  • 6mm

  • 8mm

  • 10mm

  • 12mm

• Therapy Outlook (Revenue, USD Billion, 2021 - 2033)

  • Insulin

  • Glucagon-like-peptide-1

  • Growth Hormone

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

  • Asia Pacific

    • China

    • Japan

    • South Korea

    • Thailand

    • Australia

    • India

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

(a) Segment Definition

(b) Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations